Insider trade

Officer sold ~$153K of UTHR shares in the open market

Traded May 21, 2026 · Filed May 22, 2026

Why it stands out

United Therapeutics's & GENERAL COUNSEL sold $153K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$152,834

Shares × reported transaction price

Timing vs results

15 days after results of May 6, 2026, 76 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.0%	+1.4%	−3.5%
30 days	−5.3%	−0.2%	−5.1%
90 days	−8.3%	+2.3%	−10.6%

Past results only. Not a forecast.

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
This transaction was executed in multiple trades at prices ranging from $565.91 to $566.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 4mo ago

Traded Jun 18 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 4mo ago

Scheduled in advanceFiled 4mo ago